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classes of CBVTUMOR were reported to the total CBVTUMOR to 
show volume variations in percentage. 
Results: Variations of median rCBV between M0 and M2 were 
different for two groups of patients: rCBV increased when 
initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased 
when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was 
statistically significant (p<0.013).  
Mapping of color-coded voxels between M0 and M2 provided 
additional spatial and quantitative information about tumor 
perfusion: Group_rCBV_M0>1 presented a significant decrease 
of High_CBVTUMOR volume (p=0.015) simultaneously with a 
significant increase of the Normal_CBVTUMOR volume (p=0.012) 
after treatment. Group_rCBV_M0<1 presented a significant 
decrease of Low_CBVTUMOR volume (p=0.035) after treatment 
and an increase of the Normal_ and High_CBVTUMOR volumes. 
Two examples of these CBVTUMOR volumes variations between 
M0 and M2 are illustrated for a patient of each group over 
their anatomical MRI, respectively Fig1A for a patient of 
Group_rCBV_M0>1 and Fig1B for a patient of 
Group_rCBV_M0<1.  
 
 
Conclusions: Pre and post-treatment CBV measurements with 
DSC-MRI characterized tumor perfusion evolution in GBM 
patients treated with RT combined to Tipifarnib; showing 
variations in favour of tumor perfusion normalisation in 
agreement with our pre-clinical results of vascular 
normalisation.  
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Purpose/Objective: Lung cancer is the leading cause of 
cancer death worldwide and alternative treatment strategies 
are needed to eradicate non-responsive or recurrent tumor 
cells. The Notch signaling pathway plays a key role during 
normal lung development and is frequently deregulated in 
non small cell lung cancer (NSCLC) making it a potentially 
attractive therapeutic target. We and others have shown that 
in NSCLC xenografts high Notch activity is correlated with 
faster proliferation, higher hypoxic fraction and resistance to 
radiotherapy. These findings have led us to further 
investigate the interactions between standard of care 
treatments (chemo/radiotherapy) in conjunction with Notch 
inhibitors both in vitro and in vivo.  
Materials and Methods: Monolayer cultures of diverse lung 
cell lines were used to determine the IC50 value by 
measuring the metabolic activity of the acid phosphotase 
enzyme in cells after treatment with a range of 
chemotherapeutic agents both as a monotherapy and in 
combination with Notch receptor inhibition. In addition, the 
effect of single and combined treatment schedules was 
tested using a quantitative spheroid growth delay assay. In 
vivo evaluation of therapeutic efficacy of the combination 
treatment before mentioned has been initiated using a 
xenograft lung cancer model.  
Results: IC50 value analysis of various chemotherapeutic 
agents revealed striking differences in responses across cell 
lines. The human lung cancer cell line H460 was more 
sensitive to etoposide, docetaxel and paclitaxel than 
different mouse cell lines deriving from mouse tumors 
bearing KRas and p53 mutations with different metastasizing 
potentialities (344P; 344SQ and 393P) but equally sensitive to 
cisplatin than 344P and 344SQ cell lines. The 393P cell line 
derived from a primary tumor that didn't metastasize was 
more resistant than the rest of the cell lines to cisplatin and 
paclitaxel. Interestingly, although Notch inhibition alone had 
no effect upon cell growth after 72h of treatment, the 
combination with either cisplatin or etoposide resulted in a 
growth delay with respect to the monotherapy treatment. In 
spheroid cultures of H460 cells the combination of 2.5uM 
cisplatin with 4 uM DAPT (Notch inhibitor) instigated more 
growth delay than the monotherapy treatments. Experiments 
to quantify the growth delay when also radiation is given are 
underway. In addition, in vivo experiments are ongoing to 
investigate whether the synergistic drug combination found in 
vitro also applies for an in vivo model. Two different doses of 
cisplatin were tested in vivo whereby 3.5mg/kg had a good 
efficacy and better tolerance than 7mg/kg and therefore will 
be used to test the combination treatment with the dose of 
Notch inhibitor that yields an optimal response as 
monotherapy and with radiation. 
Conclusions: The addition of Notch inhibitors to cisplatin 
(chemotherapeutic used to treat lung cancer patients) leads 
to an enhanced treatment response in vitro and may lead to 
one in vivo as well.  
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Purpose/Objective: Novel targeted agents, such as PARP 
inhibitors, are combined with radiotherapy (RT) to induce 
tumor-specific radiosensitization. Safety and tolerability of 
olaparib in combination with RT is currently tested in several 
clinical phase 1 trials. When used as single agent in clinic, 
olaparib is well tolerated and has proven anti-tumor efficacy 
in BRCA1 and 2 mutation carriers. As the mechanisms of 
action of olaparib as radiosensitizer or as single agent may 
differ, also the dose range of tolerability and effectiveness 
might differ. In this in vitro study, we compared efficacy of 
